Serina Therapeutics (SER) Total Non-Current Liabilities (2022 - 2026)
Serina Therapeutics (SER) posted Total Non-Current Liabilities of $6.7 million for Q4 2025, down 24.97% sequentially from $8.9 million in Q3 2025, and up 154.56% YoY from $2.6 million in Q4 2024.
Serina Therapeutics (SER) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Serina Therapeutics has reported Total Non-Current Liabilities for 4 years, with the latest figure at $6.7 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 154.56% year-over-year to $6.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.7 million (up 154.56% YoY) and the FY2025 annual result came in at $6.7 million, up 154.56% from the prior year.
- Total Non-Current Liabilities fell to $6.7 million in Q4 2025 per SER's latest filing, from $8.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $32.2 million in Q1 2023 and troughed at -$8.9 million in Q1 2024.
- A 4-year average of $9.9 million and a median of $8.9 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 282.38% in 2024, down 127.69% in 2024.
- Over 4 years, Total Non-Current Liabilities stood at $20.4 million in 2022, then sank by 76.16% to $4.9 million in 2023, then slumped by 45.78% to $2.6 million in 2024, then jumped by 154.56% to $6.7 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $6.7 million, $8.9 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.97 Mn |
| Dec 31, 2025 | 6.71 Mn |
| Sep 30, 2025 | 8.94 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 2.58 Mn |
| Dec 31, 2024 | 2.63 Mn |
| Sep 30, 2024 | 14.52 Mn |
| Jun 30, 2024 | 13.69 Mn |
| Mar 31, 2024 | -8.91 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 3.80 Mn |
| Mar 31, 2023 | 32.19 Mn |
| Dec 31, 2022 | 20.38 Mn |
| Sep 30, 2022 | 16.50 Mn |
| Jun 30, 2022 | 14.81 Mn |
| Mar 31, 2022 | 12.69 Mn |